Compare Redwire Corporation (RDW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Redwire Corporation trades at $10.74 (market cap $2.81B), while Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 29.7× Redwire Corporation's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals.
| RDW | REGN | |
|---|---|---|
Market Cap | $2.81B | $83.43B |
Sector | Technology | Health |
52-Week High | $25.90 | $852.03 |
52-Week Low | $5.06 | $555.51 |
Enterprise Value | $2.34B | $78.14B |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire Corporation (RDW) trades at $11.23, up 6.65% today, with a bullish technical signal and strong analyst support. The stock shows improving revenue trends with 2026 projections reaching $426 million, though profitability remains challenged with negative margins. Recent news highlights strategic investments in phased-array technology and record backlog growth, while institutional interest is strong with BlackRock's $196.5 million position.
The outlook remains cautiously optimistic given 80% analyst buy ratings and a $12.17 price target, but significant risks persist including continued cash burn, execution challenges, and premium valuation. Investors face the tension between promising space/defense growth opportunities and the company's ongoing inability to achieve profitability despite revenue expansion.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
